San Bernardino header
File #: 10758   
Type: Consent Status: Passed
File created: 8/29/2024 Department: Arrowhead Regional Medical Center
On agenda: 9/10/2024 Final action: 9/10/2024
Subject: Amendment to Agreement with Cepheid for the Purchase of Cepheid Reagents, Equipment and Services
Attachments: 1. COV - ARMC - 9-10-24 - Cephied A-2 to 23-26, 2. CON - ARMC - 9-10-24 - Cephied A-2 to 23-26, 3. Item #12 Executed BAI, 4. 23-26 A-2 Executed Contract
REPORT/RECOMMENDATION TO THE BOARD OF SUPERVISORS
OF SAN BERNARDINO COUNTY
AND RECORD OF ACTION

September 10, 2024

FROM
ANDREW GOLDFRACH, ARMC Chief Executive Officer, Arrowhead Regional Medical Center

SUBJECT
Title
Amendment to Agreement with Cepheid for the Purchase of Cepheid Reagents, Equipment and Services
End

RECOMMENDATION(S)
Recommendation
Approve Amendment No. 2 to Reagent Rental Agreement No. 23-26 with Cepheid for testing reagents and to add a new instrument and services, increasing the contract amount by $1,632,290 from $952,300 to $2,584,590, and extending the term of the agreement for an additional two years, for the total term of January 1, 2023 through December 31, 2027.
(Presenter: Andrew Goldfrach, ARMC Chief Executive Officer, 580-6150)
Body

COUNTY AND CHIEF EXECUTIVE OFFICER GOALS & OBJECTIVES
Provide for the Safety, Health and Social Service Needs of County Residents.

FINANCIAL IMPACT
Approval of this item will not result in the use of Discretionary General funding (Net County Cost). The cost of $1,632,290 is funded by State Medi-Cal, Federal Medicare, private insurances, and other departmental revenue. Funding sources may change in the future pending any legislative activity related to the repeal and/or replacement of the Affordable Care Act. Adequate appropriation and revenue have been included in the Arrowhead Regional Medical Center (ARMC) 2024-25 budget and will be included in future recommended budgets.

BACKGROUND INFORMATION
Amendment No. 2 (Amendment) to Reagent Rental Agreement No. 23-26 (Agreement) with Cepheid provides ARMC continuing performance of necessary diagnostic testing for COVID-19, Influenza, Respiratory syncytial virus, Clostridium difficile, and Methicillin-resistant Staphylococcus aureus for accurate and rapid diagnosis and treatment of infections for an additional two-year period. This Amendment increases the Purchase Commitment of the original Agreement.

The Amendment also provides for ...

Click here for full text